Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
153 enrolled
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
335 enrolled
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Phase 2 Recruiting
2,000 enrolled
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
147 enrolled
STOP VEN
Phase 2 Recruiting
50 enrolled
TRILLIUM
Phase 2 Recruiting
83 enrolled
A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia
Phase 2 Recruiting
45 enrolled
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Phase 2 Recruiting
50 enrolled
Olutasidenib With Azacitidine Followed by Olutasidenib Maintenance for the Treatment of IDH1-mutated Acute Myeloid Leukemia in Patients With Prior Treatment With Venetoclax Plus a Hypomethylating Agent
Phase 2 Recruiting
28 enrolled
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
Phase 2 Recruiting
27 enrolled
Venetoclax and Azacitidine Combined With Homoharringtonine, Followed by Allo-HSCT for Intermediate and High-risk AML.
Phase 2 Recruiting
56 enrolled
Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD
Phase 2 Recruiting
37 enrolled
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
Phase 2 Recruiting
30 enrolled
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
Phase 2 Recruiting
63 enrolled
TAGALONG
Phase 2 Recruiting
53 enrolled
BRE-04
Phase 2 Recruiting
40 enrolled
5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC
Phase 2 Recruiting
50 enrolled
Cladribine Venetoclax in Monocytic AML
Phase 2 Recruiting
20 enrolled
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Phase 2 Recruiting
40 enrolled
Venetoclax and Azacitidine Combined With Chidamide (VAC) for the Treatment of Newly Diagnosed Acute Monocytic Leukemia
Phase 2 Recruiting
92 enrolled
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
Phase 2 Recruiting
240 enrolled
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML
Phase 2 Recruiting
172 enrolled
VERDI
Phase 2 Recruiting
29 enrolled
Venetoclax Combining Chidamide and Azacitidine (VCA) in the Treatment of R/R AML
Phase 2 Recruiting
30 enrolled
A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy
Phase 2 Recruiting
120 enrolled
Venetoclax Combined With Azacitidine, Chidamide, Vindesine, and Dexamethasone in Newly Diagnosed ETP-ALL Like Patients
Phase 2 Recruiting
27 enrolled
Study of A Venetoclax-based, Anthracycline-free Regimen in Newly Diagnosed CBFβ::MYH11(+) AML
Phase 2 Recruiting
40 enrolled
Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML
Phase 2 Recruiting
40 enrolled
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
Phase 2 Recruiting
50 enrolled
Venetoclax + Azacytidine for Newly Diagnosed ETP-like ALL and T-ALL With Myeloid Mutations
Phase 2 Recruiting
32 enrolled
a New Treatment of Newly Diagnosed IDH1 Mutation Acute Myeloid Leukemia
Phase 2 Recruiting
42 enrolled
SEQUENCE
Phase 2 Recruiting
60 enrolled
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Phase 2 Recruiting
125 enrolled
Demethylating Agents Combined With Venetoclax for High-risk T-cell Lymphoblastic Lymphoma/Leukemia Post-Transplant Relapse Prevention
Phase 2 Recruiting
59 enrolled
OGILAR
Phase 2 Recruiting
33 enrolled
VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Phase 2 Recruiting
66 enrolled
AZA Combined With RCHOP in P53-mutated DLBCL.
Phase 2 Recruiting
52 enrolled
VAC Regimen for AML Patients Who Failed to Response to VA Regimen
Phase 2 Recruiting
32 enrolled
Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed AML After Allo-HSCT
Phase 2 Recruiting
20 enrolled
Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma
Phase 2 Recruiting
37 enrolled
Study of Venetoclax Combined With Azacitidine Regimen in Newly Diagnosed T-ALL Patients
Phase 2 Recruiting
28 enrolled
Maintenance Therapy of Hypomethylating Agent (HMA) in Favorable Risk Acute Myeloid Leukemia (AML) Patients
Phase 2 Recruiting
77 enrolled
Safety and Efficacy of Mitoxantrone Hydrochloride Liposome Based DCMG Regimen for R/R AML
Phase 2 Recruiting
20 enrolled
VINCENT
Phase 2 Recruiting
146 enrolled
Safety and Efficacy of Avapritinib in Relapsed or Refractory Pediatric CBF-AML With KIT Mutation
Phase 2 Recruiting
50 enrolled
Hypomethylating Agent and Venetoclax After Allo-HSCT in Patients With High-risk Myeloid Malignancies.
Phase 2 Recruiting
78 enrolled
Phase IIa Study to Assess Safety and Efficacy in the Relapsed/Refractory Acute Myeloid Leukemia
Phase 2 Recruiting
53 enrolled
Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure
Phase 2 Recruiting
20 enrolled
HO171
Phase 2 Recruiting
142 enrolled
Clinical Study of Azacitidine Combined With Ruxolitinib in the Treatment of Higher-risk MDS/MPN
Phase 2 Recruiting
50 enrolled